Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 418,300
  • Shares Outstanding, K 54,184
  • Annual Sales, $ 1,049 M
  • Annual Income, $ -760,500 K
  • EBIT $ -78 M
  • EBITDA $ 287 M
  • 60-Month Beta 1.57
  • Price/Sales 0.48
  • Price/Cash Flow 10.55
  • Price/Book 0.99

Options Overview Details

View History
  • Implied Volatility 104.82% ( +9.92%)
  • Historical Volatility 106.07%
  • IV Percentile 12%
  • IV Rank 13.69%
  • IV High 505.77% on 02/07/24
  • IV Low 41.21% on 09/11/24
  • Put/Call Vol Ratio 0.51
  • Today's Volume 2,250
  • Volume Avg (30-Day) 1,380
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 28,868
  • Open Int (30-Day) 28,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +90.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.71 +0.13%
on 11/15/24
12.73 -39.36%
on 11/07/24
-1.47 (-16.00%)
since 10/15/24
3-Month
5.69 +35.68%
on 09/25/24
13.28 -41.85%
on 08/19/24
-0.94 (-10.85%)
since 08/15/24
52-Week
1.42 +443.66%
on 02/06/24
15.10 -48.87%
on 07/30/24
+5.51 (+249.32%)
since 11/15/23

Most Recent Stories

More News
10 Stocks Retailers On Stocktwits Are Most Bullish/Bearish About To Start The Week

As the new week unfolds, earnings and economic data will again dictate sentiment.

MARA : 21.07 (+1.35%)
BLK : 1,047.37 (+0.03%)
NFLX : 823.96 (-1.59%)
PDD : 114.00 (+1.49%)
AUPH : 8.12 (-2.52%)
CKPT : 3.43 (-9.26%)
EVH : 12.38 (-2.29%)
EBS : 7.72 (-16.72%)
BIDU : 84.58 (+0.62%)
SPY : 585.75 (-1.28%)
COIN : 305.85 (+9.69%)
Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong

Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10.

IWC : 129.00 (-1.74%)
EBS : 7.72 (-16.72%)
VTI : 290.31 (-1.27%)
XBI : 91.83 (-5.29%)
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript

EBS earnings call for the period ending September 30, 2024.

EBS : 7.72 (-16.72%)
Emergent Biosolutions: Q3 Earnings Snapshot

Emergent Biosolutions: Q3 Earnings Snapshot

EBS : 7.72 (-16.72%)
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

EBS : 7.72 (-16.72%)
Emergent BioSolutions Reports Third Quarter 2024 Financial Results

EBS : 7.72 (-16.72%)
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

EBS : 7.72 (-16.72%)
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades

After performing impressively in September, volatility returned to grip the U.S. equity markets in October. The hotter-than-expected inflation reading for September has reignited recession fears. In September,...

ACDVF : 17.2900 (-0.80%)
CBRL : 48.81 (+1.54%)
EBS : 7.72 (-16.72%)
BRY : 4.28 (-4.25%)
AAL : 14.39 (+0.91%)
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

EBS : 7.72 (-16.72%)
Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata

For Immediate ReleaseChicago, IL – October 15, 2024 – Stocks in this week’s article are Grupo Supervielle S.A. SUPV, Emergent BioSolutions Inc. EBS and Innodata Inc. INOD.3 Stocks Poised for Better...

EBS : 7.72 (-16.72%)
INOD : 36.75 (-6.15%)
SUPV : 10.62 (+2.31%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 10.02
2nd Resistance Point 9.55
1st Resistance Point 8.64
Last Price 7.72
1st Support Level 7.26
2nd Support Level 6.79
3rd Support Level 5.88

See More

52-Week High 15.10
Fibonacci 61.8% 9.87
Fibonacci 50% 8.26
Last Price 7.72
Fibonacci 38.2% 6.65
52-Week Low 1.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar